PTD-DBM CAS: 1199495-15-2

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

I. Core Structure & Key Traits

1. Composition & Sequence: The peptide sequence is RRRRRRRRGGGGRKTGHQICKFRKC, consisting of an 8‑arginine protein transduction domain (PTD) for efficient cell membrane penetration, a 4‑glycine linker for structural flexibility, and the Dvl‑binding motif (DBM) that competitively blocks CXXC5‑Dvl binding. This design enables direct intracellular delivery to modulate Wnt pathway activity.
2. Formulation & Storage: Typically supplied as a lyophilized solid for research use. It is reconstituted with sterile water or normal saline for topical application or cell culture studies. Short‑term storage at 2–8°C and long‑term preservation at –20°C are recommended to maintain structural integrity and biological activity.
3. Mechanistic Edge: Unlike traditional small‑molecule activators, PTD‑DBM acts as a targeted competitive inhibitor of the CXXC5‑Dvl interaction, a key negative regulatory step in Wnt/β‑catenin signaling, without off‑target effects on other pathway components.

II. Mechanism of Action

1. CXXC5‑Dvl Interaction Blockade: CXXC5 is a negative regulator that binds to Dvl, suppressing Wnt/β‑catenin pathway activity and inhibiting hair follicle proliferation and wound healing. PTD‑DBM competes with CXXC5 for Dvl binding, relieving this inhibition and promoting β‑catenin accumulation in the nucleus.
2. Wnt/β‑Catenin Pathway Activation: Nuclear β‑catenin forms complexes with TCF/LEF transcription factors, upregulating target genes such as α‑SMA and type I collagen, which drive cell proliferation, migration, and extracellular matrix synthesis critical for tissue regeneration.
3. Hair Follicle & Wound Healing Promotion: In hair follicles, pathway activation shifts follicles from the resting (telogen) to growth (anagen) phase, stimulating neogenesis and regrowth. In skin wounds, it accelerates re‑epithelialization and collagen deposition, enhancing healing efficiency.

III. Research Applications & Value

1. Androgenetic Alopecia Research: Preclinical studies show PTD‑DBM promotes hair regrowth and follicle neogenesis in mouse models by counteracting CXXC5‑mediated pathway suppression, making it a candidate for addressing pattern hair loss.
2. Skin Wound Healing: It induces expression of β‑catenin, α‑SMA, and type I collagen, accelerating wound closure and tissue remodeling, with potential for chronic wound management.
3. Tissue Regeneration Studies: Investigated for its role in activating stem cell niches and promoting regenerative processes in other tissues, leveraging its targeted pathway modulation and cell‑penetrating properties.

IV. Administration & Safety in Research

1. Research Dosing: In in vitro studies, typical concentrations range from 1–10 μM to inhibit CXXC5‑Dvl binding. In in vivo models, topical application of 0.1–1 mM solutions on the scalp or wound sites is common, with frequency adjusted based on study duration and endpoints.
2. Administration Routes: Topical application is preferred for skin and scalp targets, ensuring direct delivery to the site of action. For cell culture, reconstituted peptide is added to media for intracellular uptake via the PTD domain.
3. Safety Profile: Preclinical data indicate low toxicity, with no significant adverse effects reported. Mild local reactions such as redness or irritation may occur with topical use but resolve spontaneously. It is contraindicated in individuals with hypersensitivity to the peptide or its components, and use in research settings requires adherence to institutional safety protocols.